KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Royalty Pharma (RPRX) over the last 2 years, with Sep 2025 value amounting to $3.1 million.

  • Royalty Pharma's Other Accumulated Expenses fell 90.00% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 90.00%. This contributed to the annual value of $68.6 million for FY2024, which is 503.08% up from last year.
  • As of Q3 2025, Royalty Pharma's Other Accumulated Expenses stood at $3.1 million, which was up 1.50% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Other Accumulated Expenses registered a high of $97.5 million during Q2 2024, and its lowest value of $3.1 million during Q2 2025.
  • Its 3-year average for Other Accumulated Expenses is $30.3 million, with a median of $15.0 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 503.08% in 2024, then slumped by 96.85% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's Other Accumulated Expenses stood at $4.3 million in 2021, then reached $12.4 million in 2022, then fell by 8.27% to $11.4 million in 2023, then skyrocketed by 503.08% to $68.6 million in 2024, then slumped by 90.00% to $3.1 million in 2025.
  • Its Other Accumulated Expenses was $3.1 million in Q3 2025, compared to $3.1 million in Q2 2025 and $18.6 million in Q1 2025.